EMEA-002635-PIP02-21-M02
Submitted by Anonymous (not verified) on 13 September 2024 - 9:09
EMEA-002635-PIP02-21-M02
Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemaciclib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0313/2023
Submitted by Anonymous (not verified) on 13 September 2024 - 9:00
Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemaciclib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0313/2023
Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemaciclib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0312/2023
Submitted by Anonymous (not verified) on 13 September 2024 - 8:57
Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemaciclib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0312/2023
Opinion/decision on a Paediatric investigation plan (PIP): Lynparza, Olaparib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0320/2023
Submitted by Anonymous (not verified) on 13 September 2024 - 8:53
Opinion/decision on a Paediatric investigation plan (PIP): Lynparza, Olaparib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0320/2023
Opinion/decision on a Paediatric investigation plan (PIP): Leqvio, Inclisiran sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0322/20
Submitted by Anonymous (not verified) on 13 September 2024 - 8:51
Opinion/decision on a Paediatric investigation plan (PIP): Leqvio, Inclisiran sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0322/2023
Opinion/decision on a Paediatric investigation plan (PIP): Imjudo, Tremelimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0302/2023
Submitted by Anonymous (not verified) on 13 September 2024 - 8:49
Opinion/decision on a Paediatric investigation plan (PIP): Imjudo, Tremelimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0302/2023
Opinion/decision on a Paediatric investigation plan (PIP): Imfinzi, durvalumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0301/2023
Submitted by Anonymous (not verified) on 13 September 2024 - 8:46
Opinion/decision on a Paediatric investigation plan (PIP): Imfinzi, durvalumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0301/2023
Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0300/2023
Submitted by Anonymous (not verified) on 13 September 2024 - 8:24
Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0300/2023
Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0299/2023
Submitted by Anonymous (not verified) on 13 September 2024 - 8:18
Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0299/2023
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - June 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 June 2024, 10:00 (CEST) to 26 June 2024, 12:00 (CEST)
Submitted by Anonymous (not verified) on 13 September 2024 - 8:13
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - June 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 June 2024, 10:00 (CEST) to 26 June 2024, 12:00 (CEST)